Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Nneka Ufere

Liver Transplant · MGH

View

Dr. Vinay Jahagirdar

Liver Transplant · Medical College of Virginia

View

Dr. Lauren Feld

Liver Transplant · UMass Memorial

View

Dr. Sonali Paul

Liver Transplant · UCMC

View

Dr. Pierre Gholam

Liver Transplant · CWRU

View

Dr. Elliot Tapper

Liver Transplant · UM

View

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Incidence and diagnostic yield of repeat imaging-based screening for hepatic arteriovenous malformations in patients with HHT.

    Jul 15, 2026DOI: 10.1097/hc9.0000000000001010Journal ArticleHepatology Communications

    Written by: Benjamin ChoLeena UsmanTorianna Lomax TruongDarcy PhelanDebajyoti DattaMandar A ArasSteven HettsMichael OhligerMiles ConradJin Ge

    Find these authors on Roon

    JG
    Dr. Jin Ge
    Liver Transplant · UCSF Medical Center

    Summary

    BACKGROUND AND AIMS: Hepatic arteriovenous malformations (HAVMs) are a common visceral manifestation of hereditary hemorrhagic telangiectasia that can lead to heart failure and biliary ischemia. Current guidelines recommend baseline hepatic screening in adulthood, but the utility of repeat imaging after an initial negative or nonactionable finding remains unclear. We sought to clarify the prevalence of clinically significant HAVMs following negative or nonactionable imaging.APPROACH AND RESULTS: We isolated all adult patients with hereditary hemorrhagic telangiectasia evaluated at the University of California, San Francisco HHT Center of Excellence between 2013 and 2025. HAVM status was determined by natural language processing of unstructured clinical and radiology notes. Of 477 patients, 195 (40.9%) had initial imaging interpreted as either HAVM-negative or nonactionable, defined as HAVM-positive but not clinically significant to warrant further imaging. Of the 195, 30 (15.4%) underwent repeat hepatic imaging. Of the 30, 17 (56.7%) were screened incidentally and 13 (43.3%) were screened due to new signs and/or symptoms. Clinically significant HAVMs were identified in 2 patients, representing a 1.0% frequency of subsequent detection among all patients who were HAVM-negative/nonactionable and 6.7% among those re-imaged. Across 48 total repeat imaging studies, the detection rate per study was 4.2%. Across 386.5 person-years of follow-up, the incidence rate of clinically significant HAVM recognition was 0.52 per 100 person-years.CONCLUSIONS: Both instances of HAVM identification reflected evolving clinical features and reinterpretation of prior imaging, not de novo lesion development. These findings support periodic reassessment of initial negative/nonactionable screening studies, with a low threshold for reassessment in the presence of new signs and symptoms.
    JGDr. Jin Ge

    Dr. Jin Ge

    Gastroenterology · Hepatology & Liver Transplantation
    University of California San Francisco Medical Center
    jin